keyword
MENU ▼
Read by QxMD icon Read
search

hcc review

keyword
https://www.readbyqxmd.com/read/29055114/sorafenib-response-in-hepatocellular-carcinoma-micrornas-as-tuning-forks-mirnas-as-regulators-of-sorafenib-response-in-hcc
#1
REVIEW
Shruthi Kanthaje, Ankita Makol, Anuradha Chakraborti
Hepatocellular carcinoma (HCC), the primary liver malignancy attributes towards the second foremost cause of cancer related mortality. The targeted chemotherapeutic agent, sorafenib is known to exhibit a statistically significant but limited overall survival advantage in advanced HCC. However, the individual patient response towards sorafenib varies drastically with most of them demonstrating stable disease (SD), few with partial response (PR) and very rare complete response (CR). Progressive disease (PD) despite the treatment has also been demonstrated in many patients indicating drug resistance...
October 20, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29054475/new-insights-into-sorafenib-resistance-in-hepatocellular-carcinoma-responsible-mechanisms-and-promising-strategies
#2
REVIEW
Leilei Niu, Liping Liu, Shengli Yang, Jianwei Ren, Paul B S Lai, George G Chen
It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a significant survival benefit from the sorafenib treatment, which is currently regarded as a first-line chemotherapeutic therapy in patients with advanced HCC. Most patients are highly refractory to this therapy. Therefore, it is necessary to identify resistant factors and explore potential protocols that can be used to overcome the resistance or substitute sorafenib once the resistance is formed. In fact, a growing body of studies has been focusing on the resistance mechanisms or the method to overcome it...
October 17, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29052780/immunotherapy-for-hepatocellular-carcinoma-patients-is-it-ready-for-prime-time
#3
REVIEW
Joseph M Obeid, Paul R Kunk, Victor M Zaydfudim, Timothy N Bullock, Craig L Slingluff, Osama E Rahma
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second most common cause of cancer death worldwide. Current treatment options for patients with intermediate and advanced HCC are limited, and there is an unmet need for novel therapeutic approaches. HCC is an attractive target for immunomodulation therapy, since it arises in an inflammatory milieu due to hepatitis B and C infections and cirrhosis. However, a major barrier to the development and success of immunotherapy in patients with HCC is the liver's inherent immunosuppressive function...
October 20, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29051790/current-immunotherapeutic-strategies-in-hepatocellular-carcinoma-recent-advances-and-future-directions
#4
REVIEW
Hwi Young Kim, Joong-Won Park
Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immune evasion by the disease, makes HCC a less promising target for conventional immunotherapy. However, recent advances in the immunotherapy have led to novel approaches to overcome these obstacles by manipulating and enhancing tumor-specific immune responses against HCC by using various modalities, such as cancer vaccines and immune checkpoint blockade...
October 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29046795/comparison-of-clinicopathological-characteristics-between-cirrhotic-and-non-cirrhotic-patients-with-intrahepatic-cholangiocarcinoma-a-large-scale-retrospective-study
#5
Lei Yuan, Xianwu Luo, Xinyuan Lu, Bin Yi, Kaijian Chu, Quanyu Cai, Xiaoqing Jiang
The effect of cirrhosis on the characteristics of intrahepatic cholangiocarcinoma (ICC) has not been fully elucidated. The purpose of this study was to investigate how cirrhosis affects the clinicopathological characteristics and survival of surgically treated ICC patients. A total of 1,312 ICC patients surgically treated between January 2007 and December 2011 at a single institution were retrospectively reviewed and the clinicopathological data were compared between cirrhotic and non-cirrhotic patients. Univariate and multivariate analyses were performed to identify significant and independent prognostic factors in this cohort...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29042794/comparison-of-microwave-ablation-and-hepatic-resection-for-hepatocellular-carcinoma-a-meta-analysis
#6
REVIEW
Manka Zhang, Huimin Ma, Jian Zhang, Lingling He, Xiaohui Ye, Xin Li
BACKGROUND AND AIMS: Hepatic resection (HRN) and microwave ablation (MWA) have significant advantages in treating hepatocellular carcinoma; however, it remains unclear which way produces better outcomes. This meta-analysis of cohort studies compared the treatments in terms of effectiveness and safety. METHODS: Six electronic databases (PubMed, Medline, EMBASE, Web of Science, EBSCO, and The Cochrane Library) were retrieved for studies comparing MWA and HRN. The meta-analysis was conducted based on statement of preferred reporting items for systematic reviews and meta-analyses...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29040995/role-of-immune-checkpoint-blockade-in-the-treatment-for-human-hepatocellular-carcinoma
#7
Naoshi Nishida, Masatoshi Kudo
With the development of molecular targeting therapy, several treatment options for advanced hepatocellular carcinoma (HCC) have become available in cases where curative and other palliative treatments, such as radiofrequency ablation, surgical resection, and transarterial chemoembolization, are not applicable. However, with the detection of a variety of mutations in cancer-related genes in a single tumor, molecular heterogeneity is commonly observed in HCC. Therefore, mutations in the major cellular signaling pathways underlie the development of resistance to molecular targeting agents...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/29037210/a-vicious-circle-between-insulin-resistance-and-inflammation-in-nonalcoholic-fatty-liver-disease
#8
REVIEW
Zhonge Chen, Rong Yu, Ying Xiong, Fangteng Du, Shuishan Zhu
Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of diseases, including simple steatosis, nonalcoholic steatohepatitis (NASH), liver cirrhosis and hepatocellular carcinoma. Lipotoxicity, insulin resistance (IR) and inflammation are involved in the disease process. Lipotoxicity promotes inflammation and IR, which in turn, increase adipocyte lipolysis and exacerbates lipotoxicity. Furthermore, IR and inflammation form a vicious circle, with each condition promoting the other and accelerating the development of NAFLD in the presence of lipotoxicity...
October 16, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/29035003/hepatitis-b-core-related-antigen-hbcrag-an-emerging-marker-for-chronic-hepatitis-b-virus-infection
#9
REVIEW
L-Y Mak, D K-H Wong, K-S Cheung, W-K Seto, C-L Lai, M-F Yuen
BACKGROUND: Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non-invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core-related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB...
October 16, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29034351/bridging-patients-with-hepatocellular-cancer-waiting-for-liver-transplant-all-the-patients-are-the-same
#10
REVIEW
Martina Coletta, Daniele Nicolini, Andrea Benedetti Cacciaguerra, Susanna Mazzocato, Roberta Rossi, Marco Vivarelli
Liver transplant (LT) is considered the best curative treatment for patients with cirrhosis and hepatocellular carcinoma (HCC) within Milan criteria. The possibility to perform LT in HCC patients is limited by the liver grafts supply; indeed, the shortage of donors often leads to a long time on waiting list and then to dropout because of tumor progression. Bridging therapies are neo-adjuvant treatments given to patients on LT waitlist, with the aim to prevent tumor progression and to reduce dropout rate. Many bridging modalities have been proposed...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29034348/selection-of-patients-with-hepatocellular-cancer-a-difficult-balancing-between-equity-utility-and-benefit
#11
REVIEW
Alessandro Vitale, Quirino Lai
Although liver transplantation (LT) represents the gold-standard strategy for hepatocellular cancer (HCC), its use is circumscribed by several factors like donor shortage, perioperative complications, or competition with other candidates without HCC. Moreover, different alternative approaches like resection or loco-regional therapies may be attempted in selected cases. The best option for the treatment of an HCC patient is a complex decision, involving several ethical principles including: equity (horizontal equity and vertical equity or urgency), and utility...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29034347/using-a-weaning-immunosuppression-protocol-in-liver-transplantation-recipients-with-hepatocellular-carcinoma-a-compromise-between-the-risk-of-recurrence-and-the-risk-of-rejection
#12
REVIEW
Roberta Angelico, Alessandro Parente, Tommaso Maria Manzia
Hepatocellular carcinoma (HCC) recurrence rate after liver transplantation (LT) is still up to 15-20%, despite a careful selection of candidates and optimization of the management within the waiting list. To reduce tumour recurrence, the currently adopted post-transplant strategies are based on the administration of a tailored immunosuppression (IS) regimen. Drug-induced depression of the immune system is essential in preventing graft rejection, however has a well-established association with oncogenesis. The immune system has a key role as a defending mechanism against cancer development, preventing vascular invasion and metastasis...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29034239/hepatoid-adenocarcinoma-of-the-stomach-a-challenging-diagnostic-and-therapeutic-disease-through-a-case-report-and-review-of-the-literature
#13
Najla Fakhruddin, Hisham F Bahmad, Tarek Aridi, Yara Yammine, Rami Mahfouz, Fouad Boulos, Ahmad Awada, Fadi Farhat
Hepatoid adenocarcinoma of the stomach (HAS) is a rare aggressive tumor with hepatocellular differentiation. HAS often produces alpha fetoprotein (AFP) and metastasizes to the lymph nodes and the liver. Molecular studies revealed Her2 amplification and overexpression, association with p53 mutations, but no association with KRAS mutations. EGFR and BRAF mutations have not yet been evaluated in hepatoid carcinoma of the stomach so far. Hereby, we present a case of a 41-year-old female patient with HAS with high AFP level and liver metastases...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/29033589/yttrium-90-radioembolization-of-unresectable-hepatocellular-carcinoma-a-single-center-experience
#14
Carsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, Nina Alexandra Lampe, Eva Maria E Matuschek, Thomas Adrian Maschke, Simon Jonas Enkirch, Markus Essler, Ulrich Spengler, Hans Heinz Schild
PURPOSE: To determine the value of radioembolization (RE) for treatment of unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Records of patients undergoing RE for unresectable HCC were retrospectively reviewed. Biochemical and clinical toxicities, imaging response (according to modified Response Evaluation Criteria In Solid Tumors), time-to-progression (TTP) and overall survival (OS) were analyzed. Data were stratified according to clinical and procedural parameters...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29032802/radioembolisation-of-hepatocellular-carcinoma-a-primer
#15
REVIEW
N Venkatanarasimha, A Gogna, K T A Tong, K Damodharan, P K H Chow, R H G Lo, S Chandramohan
Transarterial radioembolisation (TARE) has gained increasing acceptance as an additional/alternative locoregional treatment option for hepatocellular carcinoma, and colorectal hepatic metastases that present beyond potentially curative options. This is a catheter-based transarterial selective internal brachytherapy that involves injection of radioactive microspheres (usually Y-90) that are delivered selectively to the liver tumours. Owing to the combined radioactive and microembolic effect, the findings at follow-up imaging are significantly different from that seen with other transarterial treatment options...
October 9, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/29029548/antiangiogenic-agents-after-first-line-and-sorafenib-plus-chemoembolization-a-systematic-review
#16
REVIEW
Andrea Casadei Gardini, Daniele Santini, Giuseppe Aprile, Nicola Silvestris, Emanuele Felli, Francesco Giuseppe Foschi, Giorgio Ercolani, Giorgia Marisi, Martina Valgiusti, Alessandro Passardi, Marco Puzzoni, Marianna Silletta, Oronzo Brunetti, Giovanni Gerardo Cardellino, Giovanni Luca Frassineti, Mario Scartozzi
Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029539/therapeutic-evaluation-of-arterio-portal-fistula-related-gastroesophageal-variceal-bleeding
#17
Xiaoquan Huang, Wen Zhang, Shiyao Chen, Chengfeng Liu, Ruofan Sheng, Feng Li, Jian Wang, Jianjun Luo, Pengju Xu
BACKGROUND & AIMS: Intrahepatic arterio-portal fistula is an uncommon etiology of portal hypertension, which presents diagnostic and therapeutic challenges. This study aimed to assess the efficacy and outcomes of gastroesophageal variceal bleeding caused by arterio-portal fistula using different therapeutic approaches. METHODS: Medical records of 451 consecutive patients with arterio-portal fistula were reviewed from January 1, 2009, to July 15, 2016, and patients suffered variceal bleeding were eligible for the study...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029523/systematic-review-and-meta-analysis-of-the-utility-of-long-non-coding-rna-gas5-as-a-diagnostic-and-prognostic-cancer-biomarker
#18
Wei Li, Na Li, Ke Shi, Qiong Chen
The growth arrest-specific 5 transcript (GAS5) is a long non-coding RNA (lncRNA) involved in the control of cell cycle progression and apoptosis in a wide variety of cells. To determine the clinical value of GAS5 expression in cancer patients, we performed a systematic review and meta-analysis exploring its association with the diagnosis, prognosis, and clinicopathological characteristics of cancer. Ten articles on prognosis, 15 on clinicopathology, and 5 on diagnosis were analyzed. Overall results showed that decreased GAS5 expression associated with unfavorable overall survival (OS) (HR = 2...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029519/genetic-polymorphisms-in-human-udp-glucuronosyltransferases-1a7-and-the-risk-of-gastrointestinal-carcinomas-a-systematic-review-and-network-meta-analysis
#19
Yingshi Zhang, Jun Hou, Fan Feng, Dandan Li, Qiyu Jiang, Xiaojuan Li, Qingchun Zhao, Bo-An Li
OBJECTIVE: To identify the association between gastrointestinal carcinomas (GIC) risk and UDP-glucuronosyltransferases (UGTs) 1A7 polymorphisms through a systematic review and network meta-analysis. RESULTS: Seventeen studies were eligible, which included 7738 patients and 18 analyses. First, it was found that compared with non-cancer participants, UGT1A7*1 were significantly decreased in cancer patient groups, especially in hepatocellular carcinoma, colorectal carcinoma, and Asian population groups; UGT1A7*2 was significantly increased in hepatocellular carcinoma and Asian population groups; and UGT1A7*3 was significantly increased in hepatocellular carcinoma, colorectal carcinoma, Caucasian, and Asian population groups...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29027443/-gene-regulatory-network-of-hepatocellular-carcinoma-a-review
#20
Xiangqiong Liu, Baofeng Lian, Yong Lin
Hepatocellular carcinoma (HCC) is one of the common malignant tumors. HCC gene regulatory network (HCC GRN), whose nodes consist of genes, miRNAs or TFs and whose edges consist of interaction relationships of nodes, is one of the important ways to study molecular mechanism of HCC. Based on various experimental data, types of HCC GRNs could be conducted such as TF-miRNA regulatory network. Integrating the studies of HCC GRN, TF-miRNA transcriptional regulatory network performs better in identifying core genes which play important roles in network disturbances...
October 25, 2016: Sheng Wu Gong Cheng Xue Bao, Chinese Journal of Biotechnology
keyword
keyword
100425
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"